1. Home
  2. PTRN vs STOK Comparison

PTRN vs STOK Comparison

Compare PTRN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PTRN

Pattern Group Inc.

N/A

Current Price

$11.50

Market Cap

2.4B

ML Signal

N/A

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$34.51

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTRN
STOK
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PTRN
STOK
Price
$11.50
$34.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
10
Target Price
$19.89
$36.10
AVG Volume (30 Days)
834.7K
586.4K
Earning Date
01-01-0001
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.67
EPS
N/A
0.85
Revenue
N/A
$36,555,000.00
Revenue This Year
$39.63
$428.68
Revenue Next Year
$24.32
N/A
P/E Ratio
N/A
$40.16
Revenue Growth
N/A
316.34
52 Week Low
$9.19
$5.35
52 Week High
$20.10
$39.81

Technical Indicators

Market Signals
Indicator
PTRN
STOK
Relative Strength Index (RSI) 49.19 54.65
Support Level $11.21 $30.50
Resistance Level $15.09 $34.95
Average True Range (ATR) 0.75 2.24
MACD 0.16 0.09
Stochastic Oscillator 88.17 43.02

Price Performance

Historical Comparison
PTRN
STOK

About PTRN Pattern Group Inc.

Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: